

FOR IMMEDIATE RELEASE

**Obtained Medical Device Registration Certificate of
Hyalofemme® from the SFDA**

(Hong Kong, 14 March 2012) – Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 0950; Website: www.leespharm.com) ("Lee's") announced today that the Group has successfully obtained the Registration Certificate of Medical Device for marketing of Hyalofemme® (Hyaluronic Acid Derivative Vaginal Gel), in the People's Republic of China.

Lee's has signed an Exclusive Supply and Distribution Agreement with Fidia Farmaceutici S.p.A., an Italian pharmaceutical company, to market Hyalofemme® exclusively in China in February 2007. The application of Medical Device registration was submitted to the SFDA of China on October 17, 2007. The approval once again marks the achievement for the Company to successfully register Medical Device in China.

Hyalofemme®, as the vaginal epithelium is a colourless gel with strong hydrating properties that contains Hydeal-D®, a hyaluronic acid derivative. Hyaluronic acid is a natural molecule responsible for maintaining a correct level of hydration in the tissues, besides playing a fundamental role in tissue repair processes. Hydeal-D® maintains hyaluronic acid's biocompatibility and biinteractivity, characteristics that are typical of molecules naturally present in the tissues. This guarantees absolute freedom from side effects.

In September 2009, a clinical study sponsored by the Company, and led by Peking University First Hospital was conducted in four centers to evaluate the safety and efficacy on Hyalofemme® for the treatment of vaginal dryness. The study is designed as a multicenter, randomized, active-controlled, open-label, parallelled trial. 144 subjects were randomized in a 1:1 ratio, of 72 to the test arm with Hyalofemme® and 72 to the control arm with estriol cream (Ovestin). The results show that Hyalofemme® can significantly improve the clinical symptoms of vaginal dryness and the effect was non-inferior to the estrogen treatment. It is concluded that the gel may be considered not only a valid alternative treatment for patients unwilling or unable to use estrogen therapy but also for general use in treating vaginal dryness symptoms.

"We're extremely excited with the successful registration for Hyalofemme® in China. This achievement is the result of effort of our regulatory team and further validate the company's strength in product registration and development," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "We are looking forward to the launch of Hyalofemme® in the coming month. The new product could become a new growth engine for the company."

FOR IMMEDIATE RELEASE

About Hyalofemme®

Hyalofemme® (hyaluronic acid vaginal gel), a colorless gel with high hydrating properties is manufactured by FidiaFarmaceutici S.p.A., Italy and has been marketed in Italy for many years. Hyaluronic acid is a natural molecule that can maintain adequate hydration and plays an important role in tissue repair. The gel contains Hydeal-D®, a derivative of hyaluronic acid, which maintains the biocompatibility and interactivity of hyaluronic acid, and also adequate hydration of the mucosa by releasing water molecules to the tissue.

About Vaginal Dryness

The vagina is soft and elastic during the fertile period due to the balance mechanism of the vaginal epithelium that maintains the appropriate hydration and lubrication. During some situations, such as post partum, lactation and menopause, oral contraceptives or stress, the balance may be disturbed. In all of these situations, signs of vaginal dryness, burning sensation or itching may be observed.

About FIDIA Farmaceutici S.p.A.

Fidia Group is based and has firm foundations in Italy. Fidia has a long tradition of top-quality products, fruit of years of Intelligence scientific research. Fidia and partners sell their products worldwide, through commercial agreements with multinationals in the pharmaceutical and medical sectors. Fidia Pharma USA Inc is headquartered in Parsipanny, NJ, as a wholly-owned subsidiary of Fidia Farmaceutici s.p.a., an established leader in the hyaluronic acid (HY) market segment. For more company information, please visit www.fidiapharma.com

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 17 years' operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's focuses on several key therapeutic areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 US, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Formore company information, please visit www.leespharm.com

FOR IMMEDIATE RELEASE

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com